Migraine Therapeutics Market Size, Share & Industry Analysis, By Drug Class (CGRP Receptor Antagonists/Gepants, CGRP-Targeting Monoclonal Antibodies, Botulinum Neurotoxins, and Triptans), By Product (OnabotulinumtoxinA, Rimegepant, and Ubrogepant), By Disease Indication (Episodic Migraine and Chronic Migraine), By Treatment Intent (Acute/Abortive and Preventive Treatment), By Route of Administration (Oral, Subcutaneous, and Intramuscular), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital, Retail, Specialty, and Online Pharmacies), and Regional Forecast, 2026-2034